Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind study of CMAB806 versus tocilizumab, both with methotrexate, in adults with moderate to severe active rheumatoid arthritis
CTR20190739Phase 3Active
- Sponsor
- Mabpharm Limited
- Start
- Aug 2019
- Countries
- 1
01
Overview
A Phase 3 trial of CMAB806 in rheumatoid arthritis (RA), sponsored by Mabpharm Limited. Started Aug 2019; status: active.
02
Drugs
CMAB806
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20190739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190739.